Table 1.
| Author, Year | NMA | Sponsored | N Studies (Patients) | Intervention | Comparator | Hazard Ratio or Risk Ratio (Confidence or Credible Intervals) |
|---|---|---|---|---|---|---|
| PFS | ||||||
| Stadler, 2016 [10] |
Yes | Yes | 5 (2882) |
O-Chl | Chl F Ofa-Chl R-Chl RB FCR-lite |
0.19 (0.14–0.25) 0.20 (0.13–0.49) 0.33 (0.23–0.49) 0.43 (0.34–0.54) 0.81 (0.49–1.33) 0.88 (0.51–1.52) |
| Xu, 2018 [11] |
Yes | Yes | 15 (5300) |
I | Chl Flud O-Chl FC FCR B R-Chl Ofa-Chl RB |
0.16 (0.08, 0.31) 0.19 (0.09, 0.38) 0.82 (0.35, 1.88) 0.38 (0.18, 0.78) 0.72 (0.32, 1.61) 0.71 (0.31, 1.65) 0.33 (0.15, 0.71) 0.28 (0.13, 0.63) 0.55 (0.24, 1.28) |
| Sheng, 2020 [9] |
Yes | No | 3 (1017) |
OA | OI OV |
0.43 (0.22–0.87) 0.46 (0.22–0.96) § 0.30 (0.15–0.59) 0.34 (0.17–0.68) § |
| Davids, 2020 [7] |
Yes | Yes | 8 (3778) |
A | I OI IR OV BR Chl O-Chl Ofa-Chl R-Chl |
0.35 (0.18–0.66) 0.61 (0.32–1.15) ^ 0.87 (0.46–1.63) 0.63 (0.32–1.27) ^ 0.37 (0.18–0.75) 0.56 (0.27–1.14) ^ 0.60 (0.33–1.11) 0.47 (0.24–0.89) ^ 0.15 (0.08–0.27) 0.19 (0.10–0.35) ^ 0.04 (0.02–0.07) 0.03 (0.02–0.06) ^ 0.20 (0.13–0.31) 0.16 (0.10–0.27) ^ 0.07 (0.04–0.12) 0.06 (0.03–0.10) ^ 0.08 (0.05–0.14) 0.07 (0.04–0.13) ^ |
| OA | I OI IR OV BR Chl O-Chl Ofa-Chl R-Chl |
0.19 (0.09–0.38) 0.46 (0.23–0.92)^ 0.46 (0.23–0.94) 0.48 (0.23–1.01) ^ 0.20 (0.09–0.44) 0.43 (0.20–0.91) ^ 0.32 (0.16–0.64) 0.36 (0.18–0.71) ^ 0.08 (0.04–0.16) 0.14 (0.07–0.28) ^ 0.02 (0.01–0.04) 0.02 (0.01–0.05) ^ 0.11 (0.06–0.18) 0.12 (0.07–0.22) ^ 0.04 (0.02–0.07) 0.04 (0.02–0.08) ^ 0.04 (0.02–0.08) 0.06 (0.03–0.10) ^ |
||||
| Molica, 2020 CLM [8] |
Yes | No | 3 1
(1191) |
A | OI OV |
0.87 (0.47–1.61) 0.57 (0.32v1.03) |
| OA | OI OV |
0.43
(0.22–0.87)
0.29 (0.15–0.56) |
||||
| OV | OI | 1.52 (0.82–1.81) | ||||
| Molica, 2020 EJH [12] |
No | No | 4 (1574) |
I +/− R/O |
Mixed chemo (Chl, O-Chl, RB, FCR) |
0.331 (0.272–0.403) 0.159 (0.077–0.327) 11q- 0.178 (0.121–0.261) IGVH unmut 0.270 (0.149–0.489) IGVH mut |
| Chatterjee, 2021 [13] |
Yes | Yes | 6 | A OA BR OI I IR |
OV | 0.6 (0.3–1.0) 0.4 (0.2–0.8) 6.9 (3.3–13.2) 0.9 (0.5–1.6) 2.5 (1.4–4.3) 2.8 (1.2–5.4) |
| OS | ||||||
| Stadler, 2016 [10] |
Yes | Yes | 5 (2882) |
O-Chl | F Chl Ofa-Chl R-Chl RB |
0.35 (0.07–1.86) 0.48 (0.30–0.78) 0.53 (0.28–1.04) 0.81 (0.52–1.26) 0.81 (0.37–1.76) |
| Xu, 2018 [11] |
Yes | Yes | 15 (5300) |
I | Chl Flud O-Chl FC FCR B R-Chl Ofa-Chl RB |
0.16(0.04, 0.56) 0.15(0.04, 0.53) 0.41 (0.09, 1.70) 0.14(0.04, 0.52) 0.20(0.05, 0.79) 0.21(0.05, 0.80) 0.27 (0.06, 1.05) 0.18(0.04, 0.71) 0.30 (0.06, 1.29) |
| Sheng, 2020 [9] |
Yes | No | 3 (1017) |
OA | OI OV |
0.51 (0.18–1.44) 0.38 (0.13–1.08) |
| Davids, 2020 [7] |
Yes | Yes | 8 (3778) |
A | I OI IR OV BR Chl O-Chl Ofa-Chl R-Chl |
0.44 (0.16–1.27) 0.66 (0.25–1.75) ^ 0.65 (0.24–1.75) 0.45 (0.15–1.40) 0.64 (0.22–1.87) ^ 0.48 (0.18–1.30) 0.45 (0.16–1.27) 0.61 (0.23–1.60) ^ 0.23 (0.09–0.59) 0.27 (0.11–0.70) ^ 0.60 (0.28–1.26) 0.59 (0.28–1.26) ^ 0.25 (0.09–0.71) 0.30 (0.11v0.85) ^ 0.38 (0.15–0.94) 0.44 (0.18–1.07) ^ |
| AO | I OI IR OV BR Chl O-Chl Ofa-Chl R-Chl |
0.35 (0.12–1.04) 0.53 (0.19–1.45) ^ 0.51 (0.18–1.45) 0.36 (0.11–1.15) 0.51 (0.17–1.54) ^ 0.38 (0.13–1.08) 0.36 (0.12–1.05) 0.48 (0.17–1.34) ^ 0.18 (0.07–0.48) 0.22 (0.08–0.58) ^ 0.47 (0.21–1.06) 0.20 (0.07–0.59) 0.24 (0.08–0.71) ^ 0.30 (0.12–0.78) 0.35 (0.14–0.88) ^ |
||||
| Molica, 2020 EJH [12] |
No | No | 3 (1027) |
I +/− R I +/− O |
Mixed chemo +/− R/O | 0.289 (0.07–1.175) |
| Chatterjee, 2021 [13] |
Yes | Yes | 6 | A OA BR OI I IR |
OV | 0.6 (0.3–1.2) 0.5 (0.1–1.1) 1.2 (0.5–2.4) 1.0 (0.4–2.1) 1.2 (0.5–2.3) 1.2 (0.4–2.6) |
Bolded hazard ratios show significantly reduced hazards of death of intervention versus comparator. § as by investigators’ assessment. 1 ILLUMINATE, ELEVATE-TN, and CLL14. ^ results of network B including cross-trial comparisons. & includes lymphomas different from CLL. Legend: A—acalabrutinib; BR—bendamustine plus rituximab; Chl—chlorambucil; F—fludarabine; FC—fludarabine and cyclo; A—acalabrutinib; BR—bendamustine plus rituximab; Chl—chlorambucil; F—fludarabine; FC—fludarabine and cyclophosphamide; FCR—fludarabine plus cyclophosphamide plus rituximab; FI—fludarabine ineligible; HG—grade 3–5; HR—hazard ratio; I—ibrutinib; IGVH—immunoglobulin heavy chain variable region; IR—ibrutinib plus rituximab; maint—maintenance; mut—mutated status; O—obinutuzumab; O-Chl—obinutuzumab plus chlorambucil; OA—obinutuzumab plus acalabrutinib; Ofa—ofatumumab; Ofa-Chl—ofatumumab plus chlorambucil; OI—obinutuzumab plus ibrutinib; OS—overall survival; OV—obinutuzumab plus venetoclax; PFS—progression-free survival; R—rituximab; R-Chl—chlorambucil plus rituximab; R/R—relapsed/refractory; RB—rituximab plus bendamustine; RV—rituximab plus venetoclax; V—venetoclax; unmut—unmutated status.